ABSTRACT
INTRODUCTION
Acute promyelocytic leukemia (APL) is a molecularly well-defined disease, characterized by the presence of a specific chromosomal translocation-t(15;17) (q22;q21), which leads to the aberrant expression of the promyelocytic leukemia retinoic acid receptor a (PML-RARa) fusion gene ( Fig. 1 ) [1] . In about 2% of cases, other aberrant translocations, such as t(11;17)(q23;q21), t(11;17)(q13;q21) and t(5;17)(q35;q21), and from an interstitial deletion event on chromosome 17 can involve fusions between retinoic acid receptor a (RARa) and other partner genes, such as the Moreover, it allowed performing quality control of the process by the quantification of an independent control 1.00-1.03). Also in this article the evaluation of MRD in PB was not significant because of the lack of sensitivity, which limits the opportunity to use PB for monitoring [40] .
Regarding the management of high-risk patients, a risk-tailored treatment has been established; high-risk patients benefit from a more intensive consolidation therapy. Data from two PETHEMA trials (LPA96 and LPA99)
showed that an increased dose of anthracyclines enhanced the antileukemic efficacy [41] . Although risk stratification was performed using clinical parameters, it is of interest that six out of seven MRD-positive patients were high risk, and a linear correlation between clinical and molecular parameters has been shown [43] . The GIMEMA trial AIDA-2000 confirmed the validity of a risk-tailored therapy and demonstrated that the introduction of cytarabine in consolidation had a favorable role [44] .
MINIMAL RESIDUAL DISEASE MONITORING IN NEWLY DIAGNOSED PATIENTS TREATED WITH ATO IN FRONTLINE THERAPY
The efficacy of ATO in relapsed/refractory APL is well defined; during the last years, the possibility of its use in the first-line therapy was assessed, and this new approach opens a new scenario in the molecular monitoring of APL. It has been demonstrated that molecular clearance of APL blast cells using ATO as induction therapy is different compared to ATRA alone or ATRA plus chemotherapy regimens [43] .
The variability in PML-RARa clearance between ATRA and ATO is probably influenced by the different mechanism of action of the two drugs on APL blast: while ATRA barely promotes blast differentiation, ATO at high concentration 
MRD MONITORING IN RELAPSED PATIENTS
The rationale of molecular monitoring in APL patients is to detect disease relapse early and consequently to provide a preemptive intervention; the preemptive approach has been validated and shown to be a significant These data, associated with the evidence that most relapses occur during the first 3 years after consolidation, led to the indication in current guidelines that molecular monitoring should be performed every 3 months for the first 3 years after the end of consolidation [9, 11, 13-52].
With the increased sensitivity of last generation RQ-PCR tools, concerns about the possibility of monitoring MRD by PB were posed: although some studies proposed interesting experiences with MRD monitoring with PB, lack of validation impaired the real clinical utility of this approach. In particular, a comparative analysis between PB and BM evaluation showed the superiority of BM with an average 1.5 log sensitivity [34, 40] . These results were subsequently confirmed by other experiences [55] [56] [57] , and, consequently, ATO was approved as the standard therapy for relapsed APL [13] , with reported CR rates ranging between 80-90%.
Regarding the molecular clearance of PML-RARa with ATO, recently Shen et al. [58] evaluated the clearance of PML-RARa in patients with APL with RQ-PCR: 61 patients were randomized to receive ATRA, ATO or their combination. Although CR was similar in the three groups (C90%), the median time to achieve morphologic and molecular CR was significantly shorter in the combination arm, and this difference also lasted after consolidation. In particular, clearance of PML-RARa was higher with ATO monotherapy compared to ATRA, but only few data were available in the literature.
The optimal consolidation therapy after ATO-induced second remission is still a controversial point, and this is largely due to the restricted number of patients with resistant disease. Interesting data were reported by Lo-Coco et al. with gemtuzumab ozogamycin in the second or more advanced molecular relapse or in patients in first molecular relapse not eligible for conventional therapies. MRD evaluation was assessed after two doses at 6 mg/ m 2 ; all patients achieved a molecular CR after the third dose with a median duration of molecular response of 15 months [59] .
The best transplant procedure in relapsed/ refractory APL was not identified: autologous HSCT guarantees a better safety profile but is free from any graft versus leukemia effect; furthermore, the hypothetical risk of stem cell harvest contamination may impair the use of this procedure with positive MRD relapsed, while none of the negative patients showed the same behavior [60] . According to the current guidelines, it seems reasonable that the choice of the allogeneic HSCT should be reserved for patients who failed to achieve a second CR or for patients with a short first molecular remission [52, 61] . The MRD monitoring also has a place during follow-up in patients who have undergone allogeneic transplantation, and it is interesting that in a paper by Lo-Coco et al. 
